By the end of their GLP-1 treatment, it was over 6 kg of weight
Tesamorelin and Visceral Belly Fat: What the Clinical Data Shows The FDA approval that makes Tesamorelin different Tesamorelin is the only non-GLP-1 peptide in this category with an FDA approval for body fat reduction
Warfarin and other anticoagulants require closer INR monitoring when starting or stopping retatrutide
However, despite their clinical efficacy, GLP-1RAs have been associated with an increased risk of gallbladder disease, including gallstone formation known as cholelithiasis and inflammation of the gallbladder called cholecystitis, especially with prolonged use and higher doses
Research has documented their role in promoting blood vessel genesis, reducing fibrotic scarring, and supporting recovery from neurological injury
Additionally, plasma 8-isoprostane, a primary biomarker of lipid oxidative stress, decreased by 35%, confirming that the supplement was actively halting cellular damage
